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The incidence of ocular candidiasis (OC) in patients with candidemia varies across different
reports, and the issue of whether routine ophthalmoscopy improves outcomes has been
raised. This study investigated the incidence of OC and evaluate whether the extent of OC
impacts the clinical outcomes.
Methods
This retrospective study included non-neutropenic patients with candidemia who underwent
treatment at one of 15 medical centers between 2010 and 2016. Chorioretinitis without other
possible causes for the ocular lesions and endophthalmitis was classified as a probable OC.
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If signs of chorioretinitis were observed in patients with a systemic disease that causes simi-
lar ocular lesions, they were classified as a possible OC.
Results
In total, 781 of 1089 patients with candidemia underwent an ophthalmic examination. The
prevalence of OC was 19.5%. The time from the collection of a positive blood culture to the
initial ophthalmic examination was 5.0 ± 3.9 days in patients with OC. The leading isolate
was Candida albicans (77.9%). Possible OC was associated with unsuccessful treatments
(resolution of ocular findings) (odds ratio: 0.354, 95% confidence interval: 0.141–0.887),
indicating an overdiagnosis in patients with a possible OC. If these patients were excluded,
the incidence fell to 12.8%. Endophthalmitis and/or macular involvement, both of which
require aggressive therapy, were detected in 43.1% of patients; a significantly higher inci-
dence of visual symptoms was observed in these patients.
Conclusion
Even when early routine ophthalmic examinations were performed, a high incidence of
advanced ocular lesions was observed. These results suggest that routine ophthalmic
examinations are still warranted in patients with candidemia.
Introduction
Candida species are the fourth most common nosocomial bloodstream organism [1], and
ocular involvement is reported as one of the main complications in patients with candidemia
[2,3]. Oude Lashof et al. [4] reported that 16% of patients with candidemia had ocular
candidiasis (OC). Nagao et al. [5] reported that 26.5% of patients with candidemia had
findings consistent with those of OC. Krishna et al. [6] reported that the overall incidence
of OC was 26% in their study. Based on the considerably high incidence of OC in patients
with candidemia, current guidelines [2, 3] recommended an ophthalmological examination
for all patients with candidemia. In contrast, lower rates of OC ranging from 2.9% to
9.7% were recently reported [7–11], and the necessity of a routine ophthalmology consulta-
tion to rule out ocular involvement in patients with candidemia has consequently been
challenged.
There are two types of OC: chorioretinitis, which is associated with a lesion restricted to the
choroid and retina, and endophthalmitis, which is associated with a lesion extending into the
vitreous body [2]. An in-depth search for sight-threatening lesions near the macula or that
invade the vitreous body should be performed to select the appropriate treatment option (e.g.
choice of antifungals, intravitreal injection, and/or vitrectomy) [2]. We previously developed
management bundles in non-neutropenic patients with candidemia [12] that included a rou-
tine ophthalmological examination to rule out OC. Using the bundles as a check-list, we per-
formed ophthalmological examination in patients with candidemia. The aim of this study was
to estimate the incidences of OC in patients with candidemia, and to estimate the incidence of
endophthalmitis (or macular involvement) in patients with OC who underwent a comprehen-
sive examination. We also investigated how the extent of ocular infection impacted the clinical
outcomes of patients with OC.
Endophthalmitis or macular involvement in patients with candidemia
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This study was approved by the institutional review boards of Hyogo College of Medicine (No.
2599) and of each participating facility [Kobe University Graduate School of Health Sciences
(No. 472-3); Nagasaki University Hospital (17061914); Kyoto University Hospital (R2300);
Aichi Medical University Hospital (2017-H072); Nara Medical University (No.1624), Osaka
Medical College (No.2199); Kindai University Faculty of Medicine (No. 29-029); Graduate
School of Medicine, Osaka City University (No. 3813); Kagoshima University (No. 170113);
Hyogo Prefectural Amagasaki General Medical Center (No.29-8); Hyogo Prefectural Nishino-
miya Hospital (H29-3); and Takarazuka City Hospital (No. 201631)]. The institutional review
board waived the requirement for informed consent from patients included in this study. Eth-
ics approval was the responsibility of each participating center. If necessary, investigators
obtained formal approval of the protocol by the regional ethics committee.
Surveillance population and diagnosis of ocular candidiasis
This retrospective study included non-neutropenic patients (>17 years of age) with candide-
mia who underwent treatment at one of 15 medical centers in Japan between 2010 and 2016.
Included patients underwent at least one dilated fundoscopic examination performed by an
ophthalmologist. The diagnosis of OC was made based on the definition previously formulated
by Oude Lashof et al. [4] Proven OC was defined as ocular lesions that occur in combination
with a positive histology or culture of a vitreous aspirate. Either endophthalmitis, which is
associated with a lesion extending into the vitreous body, or chorioretinitis without other pos-
sible causes for the ocular lesions, was classified as a probable case of OC. Although a diagnosis
of OC was made by an ophthalmologist, signs of chorioretinitis in patients with an underlying
systemic disease that causes similar lesions such as diabetes, hypertension, or concomitant bac-
teremia, led retrospectively to a diagnosis of possible OC.
Collection of ophthalmologic data
The following parameters were reviewed: whether an ophthalmological examination was per-
formed or not in patients with candidemia, the incidence of OC, the timing of the diagnosis,
the subsequent development of OC in patients without OC upon initial examination, lesion
extension into the vitreous body and macular involvement, initial antifungal treatments, and
two measures of clinical outcomes (successful treatment and 28-day mortality). Antifungal
therapy was demonstrated as the first systemic antifungal treatments administered after diag-
nosis of candidemia and OC. The treatment of OC was considered successful when the resolu-
tion of the lesions was observed during a follow-up ophthalmological examination. Patients
who had at least 2 weeks of follow-up after OC diagnosis were included for the evaluation of
clinical outcome. Variables associated with successful treatment were also identified in univar-
iate and multivariate analyses.
Statistical methods
The relative risk ratio and 95% confidence interval (CI) were estimated for each variable using
the chi-squared test and potential confounders were examined using cross-tabulation. Vari-
ables identified as potentially relevant by these univariate analyses (p< 0.1) were subsequently
entered into a logistic regression model to estimate the size of the association [odds ratio
(OR)] and the 95% confidence interval (CI). SPSS ver. 24.0 for Windows (Chicago, IL) was
used for all analyses and the level of significance was set at p< 0.05.
Endophthalmitis or macular involvement in patients with candidemia
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Results
Incidence of ocular candidiasis
In total, 781 of 1089 patients (71.7%) with candidemia underwent an ophthalmologic exami-
nation to rule out ocular involvement. The prevalence of OC in our sample was 19.5%.
Vitreous body sampling was not performed in any patient. Although proven OC was not
diagnosed in any patient, 100 patients were classified as having probable OC, 51 were classi-
fied as having possible OC. One patient’s medical record did not state whether the lesion
extended into the vitreous body (indeterminant case). Upon initial ophthalmologic examina-
tion, 133 patients had OC (88 probable, 44 possible, and one indeterminant). Follow-up
examinations were performed on 279 (43.1%) of the remaining 648 patients; of these, 19 had
OC (12 probable, seven possible). The time from the collection of a positive blood culture to
the initial ophthalmic examination was 5.0 ± 3.9 days in patients with OC. In the 133 patients
diagnosed with OC during the initial examination, the mean time from positive blood culture
to OC diagnosis was 5.1 ± 4.0 days. In the 19 patients diagnosed with OC only on follow up
eye examination, the mean time from positive blood culture to the initial examination was
3.8 ± 2.8 days, and the mean time from positive blood culture to OC diagnosis was 12.6 ± 5.1
days.
Isolated Candida species
A total of 154 strains were isolated from the blood cultures. The most commonly found Can-
dida species was C. albicans (77.9%), followed by C. glabrata and C. parapsilosis (8.4% in each),
C. tropicalis (3.9%), C. krusei (0.6%), and other Candida spp. (0.6%).
Endophthalmitis and macular involvement
With regards to the extent of the ocular infection, 151 patients except for one indeterminate
case were analyzed. Thirty-two patients (21.2%) had endophthalmitis, whereas macular
involvement was involved in 47 patients, of which 14 patients had concomitant vitritis
(Table 1). Baseline characteristics of the patients with OC are presented as a function of the
extent of ocular lesions in Table 2. There was no significant difference in the rate of delayed
diagnosis (� 2 weeks after the blood culture collection) between patients with endophthalmitis
and those with chorioretinitis (9.4% vs. 8.4%, p = 0.856). The mean time from a positive blood
culture collection to the diagnosis of the ocular disease was 6.7 ± 5.9 days in patients with
endophthalmitis and 5.9 ± 4.5 days in patients with chorioretinitis. Six of the 32 patients with
endophthalmitis did not receive a diagnosis during the initial examination. Of the 19 patients
diagnosed during follow-up examination, six (31.6%) had endophthalmitis, and one (5.3%)
had macula-threatening chorioretinitis. The mean lengths of follow-up examinations in these
patients, from the points of positive blood cultures and initial ophthalmologic examinations,
were 13.8 ± 7.2 days and 9.3 ± 3.7 days, respectively in patients with endophthalmitis, and they
Table 1. Lesion extensions into vitreous body and macular involvement in patients with ocular candidiasis.
No. of patients
(prevalence in patients with ocular candidiasis)
without macular involvement with macular involvement Total
Chorioretinitis 86 (57.0%) 33 (21.9%) 119 (78.8%)
Endophthalmitis 18 (11.9%) 14 (9.3%) 32 (21.2%)
Total 104 (68.9%) 47 (31.1%) 151 (100%)
https://doi.org/10.1371/journal.pone.0216956.t001
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were 16 days and 14 days, respectively, in the patient with macula-threatening chorioretinitis.
Visual symptoms were reported in 37 of 120 conscious patients (30.8%). The rate of visual
symptoms was significantly higher in patients who had chorioretinitis with macular involve-
ment (46.2%) and those with endophthalmitis (67.7%) compared with patients who had chor-
ioretinitis, without macular involvement (4.8%) (both p’s < 0.001). Visual symptoms at last
ophthalmologic follow-up were reported in four of 25 patients (16.0%) with endophthalmitis
(duration of follow-up: 28 to 90 days after OC diagnosis).
Selected antifungals and duration of therapy
The first systemic antifungal treatments administered after the diagnosis of candidemia were
echinocandins in 120 patients (78.9%), fluconazole/voriconazole in 26 patients (17.1%), and
Table 2. Baseline characteristics of patients with ocular candidiasis as a function of the extent of ocular disease.
Chorioretinitis without macular
involvement (n = 86)
Chorioretinitis with macular







Sex (male) 55 (64.0%) 19 (57.6%) 0.521 13 (40.6%) 0.023
Age (>65 years) 54 (62.8%) 19 (57.6%) 0.55 23 (71.9%) 0.357
Body mass index (<18.5) 30 (34.9%) 12 (36.4%) 0.88 10 (31.3%) 0.711
Total parenteral nutrition 58 (67.4%) 19 (57.6%) 0.313 23 (71.9%) 0.645
Steroid use 23 (26.7%) 9 (27.3%) 0.954 10 (31.3%) 0.628
Immunosuppressive therapy 7 (8.1%) 5 (15.2%) 0.255 4 (12.5%) 0.487
Anticancer therapy 8 (9.3%) 2 (6.1%) 0.724 3 (9.4%) 1.000
Surgery (within 28 days) 32 (37.2%) 9 (27.3%) 0.307 10 (31.3%) 0.548
Digestive tract 22 (25.6%) 5 (15.2%) 0.224 8 (25.0%) 0.949
Others 10 (11.6%) 4 (12.1%) 0.94 2 (6.3%) 0.39
Malignant tumor 36 (41.9%) 12 (36.4%) 0.584 17 (53.1%) 0.274
Solid cancer 35 (40.7%) 10 (30.3%) 0.295 17 (53.1%) 0.227
Hematological malignancy 1 (1.2%) 2 (6.1%) 0.185 0 (0.0%) 1.000
Serum Albumin <2.8 g/dL 60 (69.8%) 24 (72.7%) 0.751 18 (56.3%) 0.168
Diabetes 14 (16.3%) 9 (27.3%) 0.173 3 (9.4%) 0.556
Hypertension/heart disease 27 (31.4%) 7 (21.2%) 0.271 4 (12.5%) 0.058
Chronic hepatic dysfunction 11 (12.8%) 4 (12.1%) 1.000 5 (15.6%) 0.689
Chronic renal failure 19 (22.1%) 8 (24.2%) 0.802 6 (18.8%) 0.693
Organ transplantation 0 (0.0%) 0 (0.0%) - 0 (0.0%) -
Inflammatory bowel disease 7 (8.1%) 3 (9.1%) 1.000 3 (9.4%) 0.83
Prolonged ICU stay 18 (20.9%) 9 (27.3%) 0.46 5 (15.6%) 0.518
Ventilator use 27 (31.4%) 9 (27.3%) 0.661 4 (12.5%) 0.058
APACHE II score� 15 36 (41.9%) 13 (39.4%) 0.807 6 (18.8%) 0.02
Diagnosis in initial examination 74 (86.0%) 32 (97.0%) 0.109 26 (81.3%) 0.568
Delayed diagnosis (≧2 weeks of
blood culture)
6 (7.0%) 4 (12.1%) 0.461 3 (9.4%) 0.702
Isolated Candida species
C. albicans 65 (75.6%) 27 (81.8%) 0.467 27 (84.4%) 0.306
C. glabrata 10 (11.6%) 2 (6.1%) 0.507 1 (3.1%) 0.285
C. parapsilosis 7 (8.1%) 5 (15.2%) 0.31 1 (3.1%) 0.445
Other Candida spp 5 (4.7%) 0 (0.0%) 0.366 3(6.3%) 0.785
¶: vs. Chorioretinitis without macula involvement
ICU: intensive care unit; APACHE II: acute physiology and chronic health evaluation II
https://doi.org/10.1371/journal.pone.0216956.t002
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liposomal amphotericin B (L-AMB) in six patients (3.9%). In contrast, the selected antifungals
for the initial treatment of OC were fluconazole/voriconazole in 79 patients (52.0%), liposomal
amphotericin B (L-AMB) in 45 patients (29.6%), and echinocandins in 29 patients (19.1%).
Echinocandins were initially used in 120 patients after the diagnosis of candidemia; this treat-
ment was changed to fluconazole/voriconazole in 59 patients and L-AMB in 33 patients,
respectively, after the diagnosis of OC. In one patient who was treated initially by L-AMB,
echinocandins were used after the diagnosis of OC because of the deterioration of renal func-
tion. Combination therapy consisting flucytosine and L-AMB was administered in 15.1% of
patients. Step-down oral therapy using azole was administered in 59 of 152 patients (38.8%)
(intravenous antifungals before the administration of an oral formulation of azole: azole, 34
patients; L-AMB, 18 patients; and echinocandins, seven patients). Azoles were administered
orally after intravenous initial loading dose in none of the patients.
Two patients received intravitreal injections of antifungal drugs. Vitrectomy was not per-
formed in any patient. The rate of azole use was significantly lower and the rate of L-AMB
use was significantly higher in patients with endophthalmitis or macular involvement than in
those who had chorioretinitis without macular involvement (Table 3). Among the 32 patients
with endophthalmitis, 16 patients (50.0%) received L-AMB and 11 (34.4%) received combi-
nation therapy of L-AMB and flucytosine during the overall treatment. When evaluating the
effect of therapy duration, patients who had no ophthalmology appointments after discharge
(n = 16) and patients who passed away before undergoing 4 weeks of therapy (n = 32) were
excluded from the analysis. The total duration of therapy was 48.7 ± 30.5 days; therapy� 4
weeks in length was administered in 81 of 104 patients (77.9%). The total duration of
therapy was significantly longer in patients who had endophthalmitis than in patients who
had chorioretinitis without macular involvement (62.6 ± 37.7 vs. 41.5 ± 22.8 days, p = 0.003)
(Table 4).
Clinical outcomes
Clinical outcomes in patients with OC are shown as a function of the extent of OC in Table 5.
Sixteen patients were excluded from the analysis of successful treatment (resolution of ocular
findings) because a follow-up ophthalmology examination was not performed at least 2 weeks
of antifungal treatment specifically for the OC. The average follow-up days for eye findings
after diagnosis of OC in patients with endophthalmitis was significantly longer than that in
patients with chorioretinitis without macular involvement. Successful treatment of OC was
achieved in 110 of 136 patients (80.1%). The 28-day mortality rate was 21.1%. There was no












involvement (n = 65)
P-
value�
Fluconazole/voriconazole 79 (49.3%) 51 (59.3%) 13 (39.4%) 14 (43.8%) 27 (41.5%) 0.03
Echinocandin 29&
(19.1%)
16& (18.6%) 6 (18.2%) 7 (21.9%) 13 (20.0%) 0.83
Liposomal amphotericin B 45 (29.6%) 20 (23.3%) 14 (42.4%) 11 (34.4%) 25 (38.5%) 0.04
Flucytosine combined with
liposomal amphotericin B
23 (15.1%) 9 (10.5%) 6 (18.2%) 8 (25.0%) 14 (21.5%) 0.06
¶: For one patient, it was not determined whether the lesion had extended into the vitreous body
&: Combination therapy with fluconazole was administered to one patient
�: Chorioretinitis without macular involvement vs. endophthalmitis or macular involvement
https://doi.org/10.1371/journal.pone.0216956.t003
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significant difference in the successful treatment rate and mortality rate between patients who
had chorioretinitis without macula involvement and patients who had chorioretinitis with
macular involvement or those who had endophthalmitis. There is a significant difference in
the successful treatment rate between possible chorioretinitis and probable chorioretinitis
[68.2% (30/44 patients) vs. 88.7% (55/62 patients), p = 0.009].
Factors associated with successful treatment
The univariate analyses identified several factors that decreased the rate of successful treat-
ment, which included possible OC, chronic renal failure, prolonged intensive care unit stay,
ventilator use, and an acute physiology and chronic health evaluation II (APACHE II) score
of� 15 (Table 6). Because of potential confounds, ventilator use was excluded from the multi-
variate analysis. The resulting independent factors associated with unsuccessful treatment
were possible ocular candidiasis (adjusted OR: 0.354, 95% CI: 0.141–0.887) and chronic renal
failure (adjusted OR: 0.216, 95% CI: 0.081–0.580).
Discussion
Overall, the incidence of OC in patients with candidemia was 19.5%, which is consistent with
that of prior studies in Japan [5, 13]. Nineteen of 152 patients with OC were diagnosed at the
time of follow-up examination, which illustrates the importance of follow-up ophthalmologic
examinations in patients with candidemia. In patients diagnosed with OC only on follow up
eye examination, early initial examination after positive blood cultures (i.e., 3.8 days) might
yield a negative diagnosis with respect to OC. Of the patients with OC, 77.9% were infected
with C. albicans. This result is consistent with prior reports. For instance, Oude Lashof et al.
[4] found that patients with OC were significantly more often infected with C. albicans and
Table 4. Duration of therapy in patients with ocular candidiasis as a function of the extent of ocular infection.








Intravenous treatment (days)& 30.8±19.9 32.4±13.0 0.202 49.5±28.1 0.001
Entire treatment course including oral
antifungals (days)
41.5±22.8 50.6±33.4 0.166 62.6±37.7 0.003
¶: vs. chorioretinitis without macular involvement
&: All patients treated initially with intravenous antifungals
https://doi.org/10.1371/journal.pone.0216956.t004
Table 5. Clinical outcomes and follow-up days in patients with ocular candidiasis as a function of the extent of ocular infection.
Clinical Outcomes No of patients with Chorioretinitis P-
value¶







Successful treatment 58/75 (77.3%) 27/31(87.1%) 0.296 24/29 (82.8%) 0.605
28-day mortality 22/86 (25.6%) 6/33 (18.2%) 0.394 4/32 (12.5%) 0.127
The average number of follow-up days after diagnosis of
ocular candidiasis (days)
38.7 ± 30.6 48.5 ± 38.9 0.224 52.1 ± 37.4 0.044
¶: vs. chorioretinitis without macular involvement
https://doi.org/10.1371/journal.pone.0216956.t005
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less often infected with C. parapsilosis than patients without OC. Lingappan et al. [14] demon-
strated that the most prevalent organism was C. albicans (33 of 38 patients with ocular candidi-
asis). Blennow et al. [7] described that C. albicans was isolated from a blood culture in 11 of 12
patients with OC, compared with 27 of 48 patients without OC; they furthermore suggested
that C. albicans was an independent risk factor for OC. Finally, Nagao et al. [5] reported that
Table 6. Factors associated with successful treatment in patients with ocular candidiasis.
Factors No of patients with successful
treatment (%)
Crude odds ratio (95%CI) of
significant factors















58/75 (77.3%) 51/60 (85.0%)
Chorioretinitis with macula
involvement
27/31 (87.1%) 82/104 (78.8%)
Endophthalmitis 24/29 (82.8%) 85/106 (80.2%)
Azole 55/69 (79.7%) 54/66 (81.8%)
Echinocandin 22/26 (84.6%) 87/109 (79.8%)
Liposomal amphotericin B 32/41 (78.0%) 77/94 (81.9%)
Combination therapy with
flucytosine
18/20 (90.0%) 91/115 (79.1%)
Diagnosis in initial examination 98/119 (82.4%) 11/16 (68.8%)
Delayed diagnosis (≧2 weeks of
blood culture)
10/13 (76.9%) 99/122 (81.1%)
Non-albicans 23/30 (76.7%) 86/105 (81.9%)
Sex (male) 59/78 (75.6%) 50/57 (87.7%)
Age (>65 years) 68/81 (84.0%) 41/54 (75.9%)
Body mass index (<18.5) 34/45 (75.6%) 75/90 (83.3%)
Total parenteral nutrition 71/87 (81.6%) 38/48 (79.2%)
Steroid use 30/38 (78.9%) 79/97 (81.4%)
Immunosuppressive therapy 12/13 (92.3%) 97/122 (79.5%)
Anticancer therapy 8/10 (80.0%) 101/125 (80.8%)
Surgery (within 28 days) 35/44 (79.5%) 74/91 (81.3%)
Malignant tumor 46/57 (80.7%) 63/78 (80.8%)
Serum Albumin <2.8 g/dL 74/89 (83.1%) 35/46 (76.1%)
Diabetes 15/21 (71.4%) 94/114 (82.5%)
Hypertension/heart disease 22/30 (73.3%) 87/105 (82.9%)
Chronic hepatic dysfunction 11/16 (68.8%) 98/119 (82.4%)





Organ transplantation 0/0 (0.0%) 109/135 (80.7%)
Inflammatory bowel disease 12/13 (92.3%) 97/122 (79.5%)
Prolonged ICU stay 18/28 (64.3%) 91/107 (85.0%) 0.316
(0.133–0.809)
0.013
Ventilator use 19/32 (59.4%) 90/103 (87.4%) 0.211
(0.134–0.527)
<0.001
APACHE II score�15 30/45 (66.7%) 79/90 (87.8%) 0.278
(0.135–0.674)
0.003
95% CI: 95% confidence interval; APACHE II: Acute physiology and chronic health evaluation II
https://doi.org/10.1371/journal.pone.0216956.t006
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C. albicans bloodstream infections and higher β-D-glucan values were independent risk factors
for OC.
Independent factors associated with unsuccessful treatment in the present study were possi-
ble OC and chronic renal failure. Successful treatment was defined as the resolution of the ocu-
lar lesions. If signs of chorioretinitis were observed in patients with an underlying systemic
disease, these cases were classified as possible OC, regardless of the patient’s diagnosis by an
ophthalmologist. Underlying systemic diseases may cause clinical failure. However, ocular
lesions caused by systemic disease can be included in possible OC. Retinal lesions caused by
systemic diseases cannot be resolved with antifungal agents, and there is a risk of overdiagnosis
among patients with possible OC. Probable chorioretinitis was diagnosed in patients with
deep focal white infiltrates in the retina. In addition, cases with hemorrhages, Roth spots, or
cotton wool spots, were classified as probable in patients who had no other reason for retinal
lesions based on the definition formulated by Oude Lashof et al. [4]
In contrast, Donahue et al. [10] made a clear differentiation between candida chorioretinitis
characterized by deep white infiltrative chorioretinal lesions and chorioretinitis characterized
by nonspecific lesions that include hemorrhages, Roth spots, or cotton wool spots. These non-
specific lesions may have different etiologies that include vascular nonperfusion and hyperten-
sion. Current guidelines [2, 3] recommend that treatment should be continued until the
complete resolution of ocular lesions. However, given the risk of over-diagnosing OC, this rule
might not apply to all patients with possible OC. A two-to-three week treatment course follow-
ing the clearance of candidemia is considered to be sufficient in patients with an underlying
systemic disease that causes nonspecific chorioretinal lesions (possible OC), especially if the
systemic clinical signs caused by candidemia are resolved.
If patients with a possible OC diagnosis were excluded from our study, the incidence of OC
would decrease from 19.5% to 12.8%, suggesting that their inclusion could potentially errone-
ously inflate the incidence rate. Using the same definition of OC, Oude Lashof et al. [4]
reported that 16% of patients with candidemia had received a diagnosis of OC and 10.8% of
patients had ophthalmological abnormalities that were consistent with the definition of proba-
ble OC. Similarly, Donahue et al. [10] reported that the incidence of ocular candidiasis was
9.3% and that an additional 20% of patients had nonspecific chorioretinal lesions not directly
related to the candida infection.
Cure rates with antifungals were considered to be much lower in patients with endophthal-
mitis than in those with chorioretinitis [15]. With early recognition of OC, a high rate of
L-AMB and combination therapy use, and a substantial duration of therapy, endophthalmitis
was not found to be a risk factor for unsuccessful treatment in our study. However, as resolu-
tion of eye findings may take substantial time, significantly longer average follow-up for eye
findings in patients with endophthalmitis would have caused better outcomes. Because the
reliance on visual symptoms alone provides poor sensitivity in the diagnosis of OC, current
guidelines [2, 3] indicate the importance of an ophthalmological examination prior to becom-
ing clinically symptomatic to prevent the loss of visual acuity. However, the issue of whether
the risk of missing OC outweighs the cost of ophthalmological examinations is still debated.
Several authors have stated that ocular involvement is uncommon and the clinical out-
comes are not improved with an early routine ophthalmological examination [7–11]. Blennow
et al. [7], for instance, reported that OC was not detected in patients with candidemia who had
not received an initial ocular examination but that were subsequently examined after receiving
two weeks of antifungal therapy. Gluck et al. [8] reported that ocular candidiasis was diagnosed
in only one patient (2.9%) who had a risk factor for OC. Finally, Vena et al. [9] described that
ocular lesions related to candidemia were found in only 7.7% of patients with candidemia, and
ophthalmological findings led to a change in antifungal therapy in only 5.9% of cases. This
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finding led the authors to ask whether systematic ophthalmoscopy examinations were neces-
sary. In agreement with this position, Donahue et al. [10] stated that only patients with risk fac-
tors for ocular involvement warrant an ophthalmological examination.
Antifungal therapy performed prior to the diagnosis of OC in patients with candidemia
might prevent the vitreal extension of lesions, and it has been suggested that the development
of endophthalmitis is uncommon in patients with candidemia [10]. Rodriguez-Adrian et al.
[15] reported that the incidence of OC was only 1% in patients with candidemia. Similarly,
Donahue et al. [10] did not diagnose endophthalmitis in any of the 118 examined patients
with candidemia, and Krishna et al. [6] also did not report any cases of endophthalmitis either.
Oude Lashof et al. [4] reported that the incidence of endophthalmitis was 1.6% in patients with
candidemia and 10% in patients with OC. Finally, Khalid et al. [16] reported that the incidence
of endophthalmitis was 1.4% in patients with candidemia and 11.1% in patients with OC.
However, 4.1% of patients with candidemia, and 21.2% of patients with OC were found to
have endophthalmitis in our study. Nagao et al. [5] reported a similar incidence of endophthal-
mitis (18.5%) in Japanese patients. The rate of visual symptoms in our study was high in
patients who had chorioretinitis with macular involvement and in those with endophthalmitis.
In addition to the high incidence of endophthalmitis, chorioretinitis with macular involvement
was found in 31.1% of patients in our study. Because of the high incidence of these invasive
ocular lesions, visual symptoms were reported in 30.8% of conscious patients with OC. This
result is inconsistent with that of a report by Oude Lashof, et al., who demonstrated that only
one of 34 patients reported low visual acuity at baseline [4].
The present study has some limitations that should be considered. First, the current study
was retrospective in nature. However, many participating institutions nonetheless used the
bundles that recommended ophthalmologic examinations as part of the assessment checklist
for the management of patients with candidemia. Second, in patients who had medical condi-
tions that can be associated with retinal lesions, the accuracy of diagnosis of OC by an ophthal-
mologist might differ according to the institution where treatment was sought. Third, less than
half of patients who were not diagnosed with OC during the initial examination underwent a
second follow-up ophthalmological examination; this may have introduced a bias when assess-
ing the incidence of OC. Fourth, although intravitreal injections of antifungal drugs are rec-
ommended in patients with macular involvement and endophthalmitis [2], only two patients
received intravitreal injections of antifungal drugs. Lastly, although echinocandin was not rec-
ommended for the treatment of OC in the bundles [12], 19.2% of patients were treated with
echinocandin. C. glabrata was isolated from blood culture in five of 29 patients in whom echi-
nocandin was used, and there was no apparent reason for echinocandin use in the remaining
24 patients.
Conclusions
The incidence of OC in our study was found to be approximately 20% in patients with candi-
demia. However, this may present an overestimation of the true incidence because of the inclu-
sion of patients with a diagnosis of possible OC. If patients with possible OC were excluded,
the incidence decreased to 12.8%. To evaluate the necessity of routine ophthalmological exam-
inations in patients with candidemia, both the incidence of OC and the risk for treatment fail-
ure should be considered, particularly for patients who are examined only after manifesting
ocular symptoms. Even with an early ophthalmological examination, advanced ocular lesions
such as endophthalmitis and macular involvement—both of which may require aggressive
therapy including an intravitreal antifungal injection or vitrectomy—were detected in 43% of
patients. Our findings demonstrated that 21% of patients with OC were unconscious at the
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time of OC diagnosis, and that only 30% of conscious patients had visual symptoms. In addi-
tion, visual abnormalities were absent in one-third of patients with endophthalmitis and in
half of the patients who had chorioretinitis with macular involvement. Current guidelines [2,
3] recommend echinocandins as the initial therapy for patients with candidemia. However,
penetration of echinocandins into the vitreous body is poor [17]. Therefore, treatment regi-
mens could be altered in a considerable number of patients when the diagnosis of OC is made.
These results lead us to conclude that routine ophthalmology examinations are still warranted
in patients with candidemia.
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